It is now believed to be an allergic reaction to aerosolized environmental fungi, usually of the dematiaceous species in an immunocompetent host 1, 2 . Most patients with AFS have history of allergic rhinosinusitis, approximately 5-10% of patients affected by chronic rhinosinusitis actually carry a diagnosis of allergic fungal sinusitis (AFS).
The incidence of AFS appears to be impacted by geographic factors. Review of the world's literature reveals the majority of sites reporting cases of AFS to be located in temperate regions with relatively high humidity 3 . On the basis of a postulated schema of the pathophysiology of AFS, a variety of treatment plans addressing its multiple contributing factors has emerged 4, 5 . Medical control of the disease has made use of various combinations of antifungal medications, corticosteroids, and immunotherapy, with varying degrees of disease control. Attempts to control this disease by only partially addressing the underlying causes likely have contributed to a high rate of recidivism 6, 9 . Successful treatment of AFS requires that the treatment plan account for each factor responsible for the propagation of the disease. In theory, individually accounting for each of these factors provides for the best chance of longterm disease control. This comprehensive approach to management depends on complete removal of all fungal mucin (usually requiring surgery) and long-term prevention of recurrence through either immunomodulation (immunotherapy and/or corticosteroids) or fungistatic antimicrobials. There are various issues relating to the use of concomitant medical therapy in the treatment of Allergic Fungal sinusitis. Firstly, there are different forms of fungal sinusitis, and each requires a specific therapeutic regimen, targeted at the pathogen. Secondly, there are numerous toxicity related issues which need to still be addressed. Thirdly, many newer antifungal drugs are extremely expensive. Lastly and most importantly, there are few randomized controlled trials which able to valid a various studies 7, 8, 11 . This study was designed to compare the outcome of AFS after addition of oral itraconazole to the treatment protocol. The nature of the procedure was explained to the patients and An Informed consent, with an emphasis on the possibility of hepatic affection secondary to chemical hepatitis, was obtained from all patients. The data obtained were analyzed statistically using the SPSS 18.
MATERIALS AND METHODS

This
RESULT
Base on Tables1,2,3,4 and 5 and Figures1 and 2 that consist of results for case and control groups: 11 patients of group A had endoscopic and radiological improvement and this improvement was maintained during the follow up period, while 5 had radiologic evidence of recurrence of sinus within 6 months, 7 patients had recurring polyp in one or both sides and two patients had to stop treatment after two months due to abnormal liver function tests.
16 patients (64%) of group B (control group) had recurring polyp in one or both sides , while 3 (12%) had radiologic evidence of recurrence of sinus and nasal polyps within 6 months, 6 patients had endoscopic and radiological improvement and this improvement was maintained during the follow up period.
DISCUSSION
Allergic fungal sinusitis (AFS) has a variety of treatment plan. One of the new plan is using Itraconazole as an adjunct therapy of AFRS. However, more studies, including a prospective randomized clinical trial, are required to determine if itraconazole is an effective method or not. Successful treatment of AFS requires arranging the treatment plan account for each factor that responsible for the propagation of this disease. Because of potent anti-inflammatory and immunomodulatory effects of corticosteroids it is suitable to control the recurrence. But the optimal dosing regimen and length of therapy remain unclear 4, 10 . Follow up of AFS patients show high recurrence despite of corticosteroid using in these patients. So another method of AFStherapy is Systemic antifungal therapy is suggested. Antifungal therapy often was used in an attempt to provide some degree of control over recurrence of AFS.
Denning et al. studied the effect of systemic itraconazole in patients with ABPA and demonstrated a decrease in total IgE 10 . He used itraconazole in a 6 patients and found that they were able to decrease the amount of prednisone required to prevent disease relapse and progression. Rains and Mineckreported using up to 400 mg of itraconazole daily and then tapering down to 200 mg a day over 3 months without any major side effects, they reported only a 4% prevalence of elevated liver enzymes. Itraconazole appears to have a modest benefit as an adjunct in the management of refractory AFS 12 . Ferguson points out that the expense, limited available data, and potential drug-related morbidity of systemic antifungal therapy may limit the usefulness of this form of treatment for noninvasive fungal disease 13 . Itraconazole and fluconazole offer a slightly safer form of antifungal therapy but still may give rise to drug-induced cardiac dysrhythmias, hepatic dysfunction, urticaria, and anaphylaxis. According to our study we propose that prolonged antifungal therapy should be instituted in patients with AFS to achieve good results regarding the rate of recurrence.
CONCLUSIONS
OralItraconazole may be of benefit as an adjunct in the management of refractory AFS. It may prolong the time of recurrence. But Steroids continue to remain the mainstay of treatment and more research is needed to define the role of systemic antifungal drugs. Itraconazole appears to have a modest benefit as an adjunct in the management of refractory AFS.
